drugset / Trial / NCT00338039
Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
The primary objective is to evaluate the efficacy of a combination of cetuximab with systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. The primary endpoint is actuarial one-year survival. The secondary objectives are: * To evaluate the local tumor response in patients treated with the above regimen. * To characterize the safety of the above regimen.
Timeline
- Start
- 2005-09
- Primary completion
- 2011-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1 g | Intravenous |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | Intravenous |